Under-dosing and over-dosing of neuromuscular blocking drugs and reversal agents: beware of the risks.
| Autor: | Hunter JM; Department of Musculoskeletal and Ageing Science, University of Liverpool, Liverpool, UK. Electronic address: bja@liverpool.ac.uk., Blobner M; Department of Anaesthesiology and Intensive Care Medicine, School of Medicine and Health, Technical University of Munich, Munich, Germany; Department of Anaesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ulm, Ulm, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | British journal of anaesthesia [Br J Anaesth] 2024 Mar; Vol. 132 (3), pp. 461-465. Date of Electronic Publication: 2023 Dec 21. |
| DOI: | 10.1016/j.bja.2023.12.001 |
| Abstrakt: | The phenomena of residual curarisation and recurarisation after the use of long-acting non-depolarising neuromuscular blocking drugs such as tubocurarine and pancuronium were well recognised 60 years ago. But the incidence seemed to decline with the introduction of atracurium and vecuronium. However, recently there have been an increasing number of reports of residual and recurrent neuromuscular block. Some of these reports are a result of inappropriate doses of rocuronium, sugammadex or both, together with inadequate neuromuscular monitoring. We urge clinicians to review their practice to ensure the highest standards of clinical care when using neuromuscular blocking drugs and reversal agents. This includes the use of quantitative neuromuscular monitoring whenever neuromuscular blocking drugs are administered. (Copyright © 2023 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|